This is also the first time that Chengdu Pioneer has realized the transfer of independent research and development of new drugs, marking the official transformation of Chengdu Pioneer from a service company based on DEL(DNA Coding Compound Library) technology to a new drug research and development company.
For the first time, Chengdu Pioneer realized the independent research and development of new drugs.
HG030 product is a new class of 1 drugs used to treat solid tumors, and it is a brand-new kinase inhibitor with independent intellectual property rights. On April 20 19, he applied for the invention patent, and on March 25, 2020, he was approved for the phase I clinical trial in the State Administration of Pharmaceutical Products.
The transfer of this product involves all rights in Chinese mainland, and its subsequent R&D, production and sales will be independently promoted by Baiyun Mountain and bear all expenses. Chengdu Pioneer still reserves all rights and interests in all regions except Chinese mainland.
According to reports, the successful development of Chengdu's leading domestic business has gradually broken the single mode of overseas business income. Prior to this, more than 90% of Chengdu Pioneer's income came from overseas, of which more than 80% came from the United States, and it was a typical export-oriented enterprise with technical services.
Together with the products transferred to Guangzhou Baiyun Mountain this time, Chengdu Pioneer is currently developing about 20 new drug projects, which means that it has high realization value and potential.
Dr. Li Jin, Chairman and CEO of Chengdu Pioneer, said that the project transfer is of great significance to Chengdu Pioneer, which not only proves the accurate and efficient strength of DNA coding compound library technology in new drug research and development, but also highlights the one-stop service capability of Chengdu Pioneer in the whole industry chain from small molecule discovery to new drug project development.
In June, 5438+this year 10, Chengdu Pioneer announced the acquisition of Vernalis, a British innovative drug company, for US$ 25 million, which realized the integration of three of the four mainstream technologies discovered by small molecules and obtained the integration effect in the future research and development of innovative drugs. Vernalis has not only added drug discovery technology, but its team has achieved nearly 10 foreign transfer projects, which are at different stages of clinical practice.
At the same time, Chengdu Pioneer and Tasly (600535. SH) To reach an innovative drug development alliance will accelerate the research and development of innovative drugs and the clinical application of new drugs on the basis of integrating the resources of both sides and utilizing their respective advantages.
Editor Deng
(Download Red Star News and prizes! )